From a pharmacological safety perspective, the adverse effect profile of retatrutide based on Phase 1 and Phase 2 clinical trial data (including the NEJM 2023 Phase 2 trial) includes: Gastrointestinal effects: Nausea, vomiting, diarrhoea, and constipation (the most commonly reported side effects in trial participants) Injection site reactions: Redness, swelling, or discomfort at the injection site Cardiovascular effects: Increases in heart rate have been observed in trial participants [21] [22] Hypoglycaemia: Particularly relevant in individuals with diabetes or those taking insulin, sulfonylureas, or other glucose-lowering agents Potential thyroid effects: GLP-1 receptor agonists have been associated with thyroid C-cell changes in rodent studies
Do not use if the solution appears cloudy, discolored, contains particles, or has been frozen and then thawed
At 40mg/ml, 2.5mg equals 6.25 units
Fourth, it acts on appetite pathways in the brain, which may help reduce hunger and food intake in some people
Prioritize protein at breakfast and after workouts to support muscle maintenance
